Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151051 | 1.00 | ATM (0.49) | ATMTOP2ATOP2BCTSKELANE | |
| SCHEMBL14639759 | 0.87 | ATM (0.48) | ATMCTSKELANECASP1CTSL | |
| SCHEMBL12196877 | 0.85 | ATM (0.47) | ATMTOP2ATOP2BCTSKCASP1 | |
| SCHEMBL2509456 | 0.85 | ATM (0.47) | ATMTOP2ATOP2BCTSKCASP1 | |
| SCHEMBL13150931 | 0.84 | ATM (0.52) | ATMTOP2ATOP2BCTSKELANE | |
| SCHEMBL2506969 | 0.81 | ATM (0.48) | ATMTOP2ATOP2BCTSKELANE | |
| SCHEMBL2505646 | 0.77 | ATM (0.51) | ATMCTSKCASP1CTSLCTSB | |
| SCHEMBL13151029 | 0.77 | ATM (0.51) | ATMCTSKCASP1CTSLCTSB | |
| SCHEMBL2557387 | 0.77 | ATM (0.48) | ATMTOP2ATOP2BCTSKELANE | |
| SCHEMBL14672525 | 0.76 | LMNA (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2552908-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123751-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ATM 750/4885TOP2A 270/4885TOP2B 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.